Skip to content

Psilocybin: all studies

Page 150 of 440: studies 1,491 to 1,500 of 4,392, newest first. Back to the psilocybin overview

Research

Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies

Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...

DOI: 10.1016/j.jadr.2021.100240 (opens in new tab) Full text (opens in new tab) Psilocybin Depression economics Bipolar disorder Psychotherapist +3

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.

Journal of Affective Disorders September 17, 2021 Nannan Li, Yi-Ru Hu, Wang-ni Chen et al.

BACKGROUND Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web...

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems

Frontiers in Psychiatry September 6, 2021 Elena Argento, Devon Christie, Lindsay Mackay et al. 12 citations

The COVID-19 pandemic stands to have impacts on mental health and well-being that will extend beyond its formal resolution. Before COVID-19, mental health disorders were already challenging global healthcare systems, directly accounting for 7.4% of the total burden of disease (1, 2). An estimated 1 billion people worldwide suffer from a mental health disorder, with the two most common...

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research

Journal of Holistic Nursing September 6, 2021 Rebecca H Lehto, Megan Miller, Jessica Sender 16 citations

Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unrelenting psychological difficulties despite intervention. There is growing interest in the role of psilocybin-assisted psychotherapy for managing treatment-resistant mental health challenges in patients with cancer. Psilocybin is a naturally occurring...

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.

European Neuropsychopharmacology September 1, 2021 Martin K Madsen, Dea S Stenbæk, Albin Arvidsson et al. 132 citations

The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metabolite). The serotonin 2A receptor critically mediates these effects by altering distributed neural processes that manifest as increased entropy, reduced functional connectivity (FC) within discrete brain networks (i.e., reduced integrity) and increased...

Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review

Research, Society and Development August 19, 2021 Frederico Marques Silveira, Amanda Pereira Mendes, Mayara Rodrigues Dos Santos et al. 1 citation

Cancer is not limited to the physical dimension, but it also affects the entire biopsychosocial context in which the patient is inserted, making him more susceptible to psychiatric disorders such as depression and anxiety. These often require pharmacological intervention, and the use of psilocybin, a substance found in mushroom species, is one of the alternatives considered today. The present...

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Pharmaceuticals August 12, 2021 Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al. 30 citations

Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells

Journal of Inflammation Research August 1, 2021 Sanah Malomile Nkadimeng, Christiaan Ml Steinmann, J.n. Eloff 77 citations

The study suggested that the hot-water extracts of the four psilocybin-containing magic mushrooms have potential anti-inflammatory effects executed by down-regulating pro-inflammatory mediators.

DOI: 10.2147/jir.s317182 (opens in new tab) Lipopolysaccharide U937 cell Cyclooxygenase Inflammation +4